About Invivoscribe
Invivoscribe: Pioneering Diagnostic Products and Reagents for Over 20 Years
Invivoscribe is a leading company in the field of diagnostic products and reagents, with over two decades of experience in developing innovative solutions that help healthcare professionals diagnose and treat various diseases. The company has established itself as a pioneer in the industry, thanks to its commitment to research, development, and manufacturing of high-quality products that meet the needs of patients worldwide.
Founded in 1995 by Dr. Jeffrey Miller, Invivoscribe has grown from a small startup to a global leader with operations in North America, Europe, Asia-Pacific region, and Africa. The company's success can be attributed to its focus on providing accurate diagnostic tools that enable clinicians to make informed decisions about patient care.
One of Invivoscribe's core strengths is its expertise in molecular diagnostics. The company has developed several proprietary technologies that allow for highly sensitive detection of genetic mutations associated with various cancers and other diseases. These technologies include PCR-based assays for detecting gene rearrangements such as BCR-ABL1 fusion transcripts associated with chronic myeloid leukemia (CML) or JAK2 V617F mutation associated with myeloproliferative neoplasms (MPNs).
In addition to molecular diagnostics, Invivoscribe also offers flow cytometry-based assays for detecting minimal residual disease (MRD) in patients undergoing treatment for hematologic malignancies such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), or multiple myeloma (MM). These assays are critical for monitoring treatment response and predicting relapse risk.
Invivoscribe's product portfolio includes both laboratory-developed tests (LDTs) as well as FDA-cleared or CE-marked diagnostic kits. The company collaborates closely with academic institutions and pharmaceutical companies worldwide to develop new products that address unmet clinical needs.
Apart from its focus on product development, Invivoscribe also places great emphasis on quality control and regulatory compliance. The company operates under ISO 13485:2016 certification standards which ensure consistent quality across all stages of product development from design through manufacturing.
In conclusion, Invivoscribe is an industry pioneer committed to developing innovative diagnostic products and reagents that improve patient outcomes worldwide. With over two decades of experience backed by cutting-edge technology platforms like PCR-based assays or flow cytometry-based MRD detection systems combined with rigorous quality control measures ensures their position at the forefront of this field today!